Results 201 to 210 of about 126,909 (281)

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Targeting Sarcomeric Hypercontractility with Demonstrated Long-Term Safety and Efficacy-A Narrative Review. [PDF]

J Clin Med
Mansour GK, Altebainawi AF, Hajjar AW, Sayed SBH, Alazem FA, Sajid MR.   +5 more
europepmc   +1 more source

Myosin inhibitors for treatment of hypertrophic cardiomyopathy. [PDF]

Cochrane Database Syst Rev
Quill S, Amin AS, Asselbergs FW, Bezzina C, Elliott PM, van der Velden J, Schmidt AF.   +6 more
europepmc   +1 more source

Novel Drug Targets in Diastolic Heart Disease. [PDF]

Int J Mol Sci
Er TS, Martinac B, Hool LC.
europepmc   +1 more source

Catastrophic apical ballooning in an obstructive hypertrophic cardiomyopathy patient treated with mavacamten: case report. [PDF]

Eur Heart J Case Rep
De Roeck F, Lahaye F, Gevaert AB, De Paep R, Van Craenenbroeck E.   +4 more
europepmc   +1 more source

Hypertrophic cardiomyopathy mutations Y115H and E497D disrupt the folded-back state of human β-cardiac myosin allosterically. [PDF]

Nat Commun
Nandwani N, Bhowmik D, Glaser C, Childers MC, Goluguri RR, Dawood A, Regnier M, Houdusse A, Spudich JA, Ruppel KM.   +9 more
europepmc   +1 more source

Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential

bioRxiv
Laszlo Radnai, Erica J. Young, Carlos Kikuti, Madalyn Hafenbreidel, Rebecca F. Stremel, Li Lin, Katalin Toth, Paolo Pasetto, X. Jin, Aagam Patel, Michael Conlon, S. Briggs, Leila Heidsieck, H. L. Sweeney, James Sellers, Teresa Krieger-Burke, William H. Martin, Jay Sisco, Steven Young, Paul Pearson, Gavin Rumbaugh, Gian Luca Araldi, Steven K. Duddy, Michael D. Cameron, M. Surman, A. Houdusse, Patrick R. Griffin, T. Kamenecka, Courtney A. Miller   +28 more
semanticscholar   +1 more source

Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact. [PDF]

J Clin Med
Mauriello A, Correra A, Maratea AC, Cetoretta V, Benfari G, Ilardi F, Cocchia R, Lisi M, Malagoli A, Mandoli GE, Pastore MC, Sperlongano S, Russo V, Cameli M, D'Andrea A, Working Group of Echocardiography of the Italian Society of Cardiology.   +15 more
europepmc   +1 more source

Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy: from Pathophysiology To Real World Data. [PDF]

Curr Cardiol Rep
Panichella G, Garofalo M, Ragagnin M, Fanizzi AI, Zampieri M, Del Franco A, Cappelli F, Pieroni M, Olivotto I.   +8 more
europepmc   +1 more source

PTUPB, a soluble epoxide hydrolase/cyclooxygenase‑2 dual inhibitor, reduces endothelial‑to‑mesenchymal transition and improves doxorubicin‑induced vascular and cardiac toxicity. [PDF]

Mol Med Rep
Dhulkifle H, Therachiyil L, Hasan MH, Younis SM, Al-Shar'i NA, Yalcin HC, Maayah ZH.   +6 more
europepmc   +1 more source